EMD Serono, Inc. is a top player in the US multiple sclerosis market today and is dedicated to bringing new treatment options to people with multiple sclerosis in the future. Our neurodegenerative disease franchise is our largest, led by our flagship product Rebif® (interferon beta-1a). Rebif® is one of the
leading treatments for relapsing remitting multiple sclerosis (MS) in the US, and the leading treatment outside of the US. At EMD Serono we are dedicated to improving the lives of people with MS and offer a comprehensive education and support services for people living with MS and their caregivers through
MS LifeLinesSM. Click on the Rebif product name above for additional product and full prescribing information.
Multiple Sclerosis
Multiple Sclerosis (MS) is a chronic, inflammatory condition of the nervous system, which includes the brain, spinal cord, and optic nerves, and is the most common, non-traumatic, neurological disease in young adults. MS may affect approximately two million people worldwide, with more than 400,000 here in the US. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common. MS is usually diagnosed between the ages of 20 and 40, and it's twice as common in women as in men. Currently, there is no cure for MS. For more information visit, www.mslifelines.com or www.rebif.com.